Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy

Biomaterials

Volumn 35, Issue 28, 2014, Pages 8186-8196

  Yoshizaki, Yuta ^a   Yuba, Eiji ^a   Sakaguchi, Naoki ^b   Koiwai, Kazunori ^b   Harada, Atsushi ^a   Kono, Kenji ^a  

^a Osaka Prefecture University   (Japan)

^b TERUMO CORPORATION   (Japan)

Author keywords

Adjuvant; Cancer immunotherapy; Cationic lipid; Cellular immunity; Dendritic cell; PH sensitive liposome

Indexed keywords

ANTIGENS; CELLS; DISEASES; MOLECULES; POLYMERS; TUMORS;

ADJUVANT; CANCER IMMUNOTHERAPY; CATIONIC LIPIDS; CELLULAR IMMUNITY; DENDRITIC CELLS; PH-SENSITIVE LIPOSOMES;

LIPOSOMES;

3 METHYLGLUTARYLATED POLY(GLYCIDOL); 3,5 DIDODECYLOXYBENZAMIDINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; LIPID; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; PHOSPHATIDYLCHOLINE; POLYMER; UNCLASSIFIED DRUG; ANTIGEN; CATION; GLUTARIC ACID DERIVATIVE; PROPANEDIOL DERIVATIVE;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOSOME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYDROPHOBICITY; IMMUNE RESPONSE; LYSOSOME; MOUSE; NONHUMAN; PH; PHENOTYPE; PRIORITY JOURNAL; STATIC ELECTRICITY; TUMOR VOLUME; UPREGULATION; ZETA POTENTIAL; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; NEOPLASM; PROCEDURES;

MURINAE; MUS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; CATIONS; CELL LINE; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUTARATES; HYDROGEN-ION CONCENTRATION; IMMUNOTHERAPY; LIPIDS; LIPOSOMES; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED C57BL; NEOPLASMS; PHENOTYPE; PHOSPHATIDYLCHOLINES; POLYMERS; PROPYLENE GLYCOLS;

EID: 84903692367     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.077     Document Type: Article

References (48)

1. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5:296-306.
2. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
3. Fong L., Engleman E.G. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000, 18:245-273.
4. Wei S., Kryczek I., Zou L., Curiel T., Cheng P., Zou W. Novel tumor immunotherapy: targeting dysfunctional antigen presenting cells. Discov Med 2005, 5:489-492.
5. Palucka A.K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12:265-277.
6. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
7. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
8. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002, 16:1217-1226.
9. Akagi T., Baba M., Akashi M. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine. Adv Polym Sci 2012, 247:31-64.
10. Bachelder E.M., Beaudette T.T., Broaders K.E., Fréchet J.M.J., Albrecht M.T., Mateczun A.J., et al. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol Pharm 2010, 7:826-835.
11. Kunisawa J., Nakanishi T., Takahashi I., Okudaira A., Tsutsumi Y., Katayama K., et al. Sendai virus fusion protein mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system. J Immunol 2001, 167:1406-1412.
12. Bungener L., Serre K., Bijl L., Leserman L., Wilschut J., Daemen T., et al. Virosome mediated delivery of protein antigens to dendritic cells. Vaccine 2002, 20:2287-2295.
13. Reddy R., Zhou F., Huang L., Carbone F., Bevan M., Rouse T.B. pH-sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. J Immunol Methods 1991, 141:157-163.
14. Tachibana R., Harashima H., Shono M., Azumano M., Niwa M., Futaki S., et al. Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: qualitative and quantitative evaluation of intracellular trafficking. Biochem Biophys Res Commun 1998, 251:538-544.
15. Yuba E., Harada A., Sakanishi Y., Watarai S., Kono K. A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy. Biomaterials 2013, 34:3042-3052.
16. Seki K., Tirrell D.A. pH-Dependent complexation of poly(acrylic acid) derivatives with phospholipid vesicle membrane. Macromolecules 1984, 17:1692-1698.
17. Murthy N., Robichaud J.R., Tirrell D.A., Stayton P.S., Hoffman A.S. The design and synthesis of polymers for eukaryotic membrane disruption. J Control Release 1999, 61:137-143.
18. Nakamura T., Moriguchi R., Kogure K., Shastri N., Harashima H. Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes. Mol Ther 2008, 16:1507-1514.
19. Kono K., Igawa T., Takagishi T. Cytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivative. Biochim Biophys Acta 1997, 1325:143-154.
20. Sakaguchi N., Kojima C., Harada A., Kono K. Preparation of pH-sensitive poly(glycidol) derivatives with varying hydrophobicities: their ability to sensitize stable liposomes to pH. Bioconjug Chem 2008, 19:1040-1048.
21. Yuba E., Harada A., Sakanishi Y., Kono K. Carboxylated hyperbranched poly(glycidol)s for preparation of pH-sensitive liposomes. J Control Release 2011, 149:72-80.
22. Yuba E., Tajima N., Yoshizaki Y., Harada A., Hayashi H., Kono K. Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy. Biomaterials 2014, 35:3091-3101.
23. Appleman L.J., Boussiotis V.A. T cell anergy and costimulation. Immunol Rev 2003, 192:161-180.
24. Harris N.L., Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol Cell Biol 1999, 77:304-311.
25. Corthay A. A three-cell model for activation of naïve T helper cells. Scand J Immunol 2006, 64:93-96.
26. Okada N., Saito T., Masunaga Y., Tsukada Y., Nakagawa S., Mizuguchi H., et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001, 61:7913-7919.
27. Morelli A.E., Zahorchak A.F., Larregina A.T., Colvin B.L., Logar A.J., Takayama T., et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 2001, 98:1512-1523.
28. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchel T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-1632.
29. Weeratna R.D., McCluskie M.J., Xu Y., Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000, 18:1755-1762.
30. Akramiene D., Kondrotas A., Didziapetriene J., Kevelaitis E. Effects of β-glucans on the immune system. Medicina (Kaunas) 2007, 43:597-606.
31. Lonez C., Vandenbranden M., Ruysschaert J.M. Cationic lipids activate intracellular signaling pathways. Adv Drug Deliv Rev 2012, 64:1749-1758.
32. Chen W., Yan W., Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother 2008, 57:517-530.
33. Vasievich E.A., Chen W., Huang L. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Cancer Immunol Immunother 2011, 60(5):629-638.
34. Vasievich E.A., Ramishetti S., Zhang Y., Huang L. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. Mol Pharm 2012, 9:261-268.
35. Yuba E., Kojima C., Sakaguchi N., Harada A., Koiwai K., Kono K. Gene delivery to dendritic cells mediated by complexes of lipoplexes and pH-sensitive fusogenic polymer-modified liposomes. J Control Release 2008, 130:77-83.
36. Shen Z., Reznikoff G., Dranoff G., Rock K.L. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997, 158:2723-2730.
37. Moore M.W., Carbone F.R., Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988, 54:777-785.
38. Harding C.V., Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 1994, 153:4925-4933.
39. Li Y., Ke Y., Gottlieb P.D., Kapp J.A. Delivery of exogenous antigen into the major histocompatibility complex class I and class II pathways by electroporation. J Leukoc Biol 1994, 56:616-624.
40. Daleke D.L., Hong K., Papahadjopoulos D. Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochim Biophys Acta 1990, 1024:352-366.
41. Frey A., Di Canzio J., Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998, 221:35-41.
42. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998, 188:1359-1368.
43. Fujiwara M., Baldeschwieler J.D., Grubbs R.H. Receptor-mediated endocytosis of poly(acrylic acid)-conjugated liposomes by macrophages. Biochim Biophys Acta 1996, 1278:59-67.
44. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Alt Med Rev 2003, 8:223-246.
45. Jonuleit H., Kühn U., Müller G., Steinbrink K., Paragnik L., Schmitt E., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997, 27:3135-3142.
46. Xu W., Tamura T., Takatsu K. CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway. Int Immunopharmacol 2008, 8:351-361.
47. Braun R., Babiuk L.A., van Drunen Littel-van den Hurk S. Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J Gen Virol 1998, 79:2965-2970.
48. Garcon N., Segal L., Tavares F., Van Mchelen M. The safety evaluation of adjuvants during vaccine development: The AS04 experience. Vaccine 2011, 29:4453-4459.